Head-to-head · free
Mirum Pharmaceuticals, Inc. vs MannKind
MIRM vs MNKD — return on capital, cash generation, margins and balance sheet side by side.
MIRM
5 / 8
measures where MIRM leads
MNKD
3 / 8
measures where MNKD leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | MIRM · FY2025 | MNKD · FY2025 |
|---|---|---|
| Revenue | $521.3M | $349.0M |
| Net income | (23.4M) | $5.9M |
| Revenue growth (yearly, multi-year) | 128.5% | 46.7% |
| Free cash flow | $54.9M | $13.7M |
| Free cash flow margin | 10.5% | 3.9% |
| Net cash / (debt) | — | — |
| ROIC | — | — |
| Return on equity | -8.6% | — |
| Gross margin | 80.8% | 74.8% |
| Operating margin | -4.2% | 13.3% |
| Net debt / EBITDA | 6.22x | 5.48x |
Figures are as reported by each company; latest fiscal year shown.
Where Mirum Pharmaceuticals, Inc.'s cash went (FY2025)
- Capital spending
- $954000
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Where MannKind's cash went (FY2025)
- Capital spending
- $4.6M
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free